Ibonova

The project captures value through a dual approach of intellectual property licensing and controlled manufacturing. By licensing its patented synthetic ibogaine process and quality assurance protocols to clinics and manufacturers, the project generates revenue from upfront fees, per-gram royalties, and milestone payments. These funds support ongoing process optimization and regulatory compliance, while limited in-house manufacturing through regulated partners provides early cash flow and validates product quality, reinforcing pricing power and credibility ahead of broader licensing.

Tokenized governance and utility further align incentives and revenue distribution. The $GAIN token enables holders to participate in key decisions on licensing terms, treasury allocation, and price stabilization, with staking options that may share in licensing revenues. A portion of all revenues—licensing, manufacturing, and data access—flows to the DAO treasury, funding buybacks, staking rewards, and R&D grants as approved by governance. Patent protection and a growing proprietary dataset strengthen defensibility, supporting sustainable, equitable access and long-term value accrual.